Pfizer Headquarters, All Office Locations and Addresses

Pharmaceutical companies are dedicated in giving the utmost possible highest product and service quality to its people. World pharma and labs are integrated in order to deliver the demands. One of the main players in the pharmaceutical industry is the Pfizer Inc.

Pfizer Inc. (also regarded as the Pfizer Drug Company) is a US-based pharmaceutical corporation with the corporate headquarters in New York City (US Headquarters), with its R&D HQ in Groton, Connecticut together with several office locations around the world.

It is regarded as one of the world’s largest pharmaceutical companies ever to exist in a long span of time. It is listed on the NYSE its shares have been a component of the DJIA since the year of 2004.

Company Information

HQ:	235 East 42nd Street Manhattan, New York City, New York, United States
Zipcode:	10017
Traded as	NYSE: PFE
ISIN	US7170811035
Industry focused	Pharmaceutical
Founded:	1849 in New York City
Founder:	Charles Pfizer and Charles F. Erhart
Products:	Medical and pharmaceutical products
Business data:	Google Finance / Yahoo! Finance / SEC filings
Website:	www.pfizer.com

---

All Corporate Locations for Pfizer Inc.

---

What is Pfizer Inc.?

As a pharmacy firm, Pfizer Inc. works. The company sells oncological, inflammatory, cardiovascular and other preventive drugs, vaccines, medical devices and consumer wellness goods. Pfizer represents clients around the globe.

What does Pfizer Inc. do?

Pfizer is to achieve breakthroughs that improve the lives of patients. R&D remains at the core of Pfizer’s mission as it converts innovative research and technology into the most effective therapies. Currently, the business is in biomedical research at a unique moment. It provides a fundamental deeper view of human genetics and what triggers sickness over more than a decade since the sequencing of the human genome.

In recent years, Pfizer has focused on how it has performed R&D in the past. It has further combined research and industry, which ensures that its methodology is turned into a more collaborative, oriented and patient approach. Ultimately, it focused on developing an engine to bring major new drugs and vaccinations year after year to patients.

It works on key areas where Pfizer feels it is ideally equipped to give patients innovative and appropriate therapies.

This covers chronic autoimmune and inflammatory disorders, vaccination, oncology, respiratory and metabolism and rare diseases. It introduces to these areas of state-of-the-art medication and vaccine design and production capabilities.

The secret to its strategy is to partner with other innovators in the health landscape, including researchers, consumer foundations, states, other biopharmaceutical firms and physicians. It currently contains more than 80 groundbreaking drugs, including possible first-class vaccinations for two lethal viruses from the hospital, new lupus and high cholesterol antibodies and the next wave of targeted cancer therapies.

It also draws on a tradition in creating secure and efficient biological drugs to launch good quality bio-like items that will expand patient access with cheap substitute biological treatments.

Pfizer Inc. History

Charles Pfizer and Charles Erhart founded in 1849 in a red brick house in Brooklyn, NY. The Civil War extension continued in 1868 and Pfizer’s profits doubled. Fueled by America’s western growth, Pfizer opened its own headquarters in 1882 and its first factory outside of New York in Chicago, Illinois. At the age of 82, Charles Pfizer died in 1906 while on holiday at his estate in Newport, Rhode Island.

A tribute to Pfizer from the New York Tribune stated: “by bringing to his task a thorough German technical education, great industry, and determination, he successfully met all difficulties and each year expanded his business.”

In 1914, the Board of Directors formed and voted John Anderson as Chairman.

In 1919, Pfizer Chemist James Currie and his assistant Jasper Kane succeeded in leading the mass production of citric acid from sugar by fermenting molds – an achievement which eventually freed Pfizer from dependence on European citrus cultivators. Charles Pfizer & Co. turned 75 in 1924. The celebration of 306 workers at Brooklyn marked the landmark.

John Anderson declared his resignation as Chairman of the Board on 10 January 1929. The new president was William Erhart, Emile Pfizer proceeded to act as president, and George, the son of John Anderson, becomes senior vice president. In 1936 Doctor Richard Pasternack invented an ascorbic acid vitamin C fermentation-free process.

Pfizer became the world’s largest vitamin C maker after designing a new plant and introducing seven-day manufacturing schedule 24 hours a day.

After 3 years, Pfizer was able to manufacture citric acid so well by fermenting sugar that a pound of citric acid, costing $1.25 in 1919 Pfizer became well-known in fermentation technology. In 1941 Pfizer replied to the US Government’s call to step up the development of penicillin to cure Allied soldiers in the war.

Pfizer alone utilized fermentation technology with industries undertaking mass penicillin production. Pfizer’s attempts to manufacture penicillin effectively culminated in the usage of deep tank fermentation and in 1944 became the world’s leading manufacturer of the ‘miracle medicine.’

After one year, George A. Anderson becomes Chief Executive Officer of Pfizer. John L. Smith occupies the President’s role. In 1950 the company’s first research campaign of wide spectrum antibiotics, Terramycin® (oxytetracycline), became the first medication marketed under the Pfizer mark in the United States. Pfizer had started spreading to overseas markets and has formed the Foreign Division.

Pfizer operations were developed in Belgium, Brazil, Canada, Cuba, England, Mexico, Panama and Puerto Rico as a part of a significant foreign expansion in 1951. John “Jack” Powers, Jr., then Pfizer President Associate, John McKeen, orders his foreign teams to “study the economy and make good contacts with the government officials, learn the languages and history of customs and hire local staff as much as possible.” Pfizer set up an Agricultural Branch in 1952. J.B Roerig and Company, a specialist in dietary products, became a subsidiary of Pfizer following its purchase. Roerig appears to be an important part of the outstanding marketing division of Pfizer.

In 1955, in England, a fermentation plant began, setting the groundwork for the research and development activities of Pfizer in Great Britain. To develop and sell antibiotics, Pfizer collaborated with Japan’s Taito. In 1983, Pfizer gained sole control of Taito. In Mexico, Italy, and Turkey, modern Pfizer pharmaceutical plants started development in 1958. In 1957, foreign workers grew from 4,300 to over 7,000.

The first World Headquarters was built in midtown Manhattan in 1961. John J. Powers, Jr., was elected president in 1965. The company’s first once-a-day broad-spectrum antibiotic, Vibramycin® (doxycycline hyclate), was launched in 1967. Pfizer bought Mack Illertissen in 1971. Pfizer reached the billion-dollar revenue mark within a year.

In 1976, in the United States, for the management of elevated blood pressure, Pfizer launched Minipress® (prazosin HCI). In 1980, Feldene® (piroxicam) became one of the world’s most widely-sold anti-inflammatory prescription medicines. Glucotrol® (glipizide) was introduced in 1984 for diabetes.

In 1986, Pfizer launched Unasyn®, an injectable antibiotic. In 1989, Pfizer released extended-release tablets with Procardia® XL (nifedipine). William C. Steere, jr., was made president in 1990 and Pfizer had three big new drugs after two years: Zoloft® (sertraline hydrochloride) for stress, Norvasc® (amlodipine besylate), for angina and hypertension management, as well as Zithromax® (azithromycin) for airborne and skin infections.

In 1995, the Animal Health Group bought the animal health subsidiary of SmithKline Beecham, rendering Pfizer a market pioneer in the manufacture and manufacture of agricultural medicinal drugs for livestock. In 1998, Viagra was released by the company. The Pfizer Innovation Technology Center was opened in 1999 in Cambridge, Massachusetts. Henry A. McKinnell, Jr., Ph.D. assumed the position of Chairman and Chief Executive Officer of William C. Steere, Jr. in 2001. In 2002, Pfizer released the LivingTM Sharing Card Service Pfizer For. In 2003, Pfizer spent more than 7.1 billion dollars in R&D. In 2004, the firm introduced Caduet® (amlodipine besylate and atorvastatin calcium).

Pfizer released Lyrica® in 2005 (pregabalin). In 2009, Pfizer purchased Wyeth on 15 October 2009, opening up a business with a large variety of drugs and treatments. Next year, Pfizer will be unveiling the Pfizer Worldwide Research and Development diversified R&D network to promote excellence in small molecules, big molecules and vaccine R&D. The corporation reported in 2014 that it had signed a binding deal to purchase the $635 million inventory of branded vaccines of Baxter International Inc.

Pfizer Inc. Profile

Charles Pfizer and Charles F.Erhart are the initial founders of Pfizer Chemicals in New York in the year 1849 nearly two centuries ago, as the manufacturers of fine chemicals and more. The alliance grew, with their major turning points being the creation of the anti-parasitic drug named Santonin and Citric Acid.

As the twentieth century passes, Pfizer was doing significantly well. It was only during the WWII when Pfizer produced massive supplies of Penicillin for the victims of the war and transported it to Europe. It gave a good impression, gaining lot of popularity worldwide. By the mid-20^th century, it expanded through the world into nearly ten other countries including the UK, Iran, Belgium, Brazil and Canada.

The company was responsible of breakthrough drugs that it discovered and marketed. Naming some are Zoloft (the anti-depressant drug), Lipitor (the cholesterol lowering drug), Viagra (to treat sexual dysfunction), Aricept (anti-Alzheimer’s drug) and Zithromax (an antibiotic).

Pfizer also made several aquisitions. Warner-Lambart, Wyeth and Pharmacia are some of the major pharmaceutical companies that they acquired. Off late, Pfizer discontinued most of its research units and has been focusing on developing its spin-off named Zoetis that will be involved in agricultural and animal health field.

Issues in the world health caught Pfizer’s concern, either giving away drugs at little to no cost in the developing countries. The company donates Fluconazole to the countries where AIDS is highly prevalent at no cost. The company, together with Gates Foundation, also gives away contraceptive drugs at significantly low rates to the women of the developing countries.

For more than a century with more than 60 types of drugs that Pfizer presently in use today, the brand plays a major role in the pharmaceutical world and will persist for the future to come.

Key People/Executives for Pfizer Inc.

Albert Bourla	Chairman and CEO
Mr. Frank A. D’Amelio	CFO and Executive Vice President of Business Operations
Dr. Mikael Dolsten M.D., Ph.D.	President of Worldwide R&D and Executive Vice President
Lidia Fonseca	Chief technology officer

What is Pfizer Inc. business strategy?

Pfizer’s corporate plan would discuss its strategic steps and tactics, through which the firm can gain buyers, thrive successfully, take advantage of opportunities to expand, meet its expected financial results, respond to evolving conditions and function. Innovation is the foundation of Pfizer’s business strategy. Pfizer was built around the premise that they would win market share, consumer satisfaction and a strategic lead over their rivals if they evolve.

Pfizer starts with the intention of making modern, creative goods that would change our lives. By leveraging sub strategies that help render the business strategy a practice, Pfizer retains this policy. Pfizer has sourcing plans and a lesser approach helps sustain a corporate innovation strategy.

How Does Pfizer Inc. Make Money?

Under law, pharmaceutical firms are forbidden from explicitly marketing drugs to customers. To develop and construct a name, pharmaceutical firms are utilizing both overt and indirect marketing methods. Most of these disjointed networks practically use a rather simplistic and consistent method.

Convince physicians to “prescribe a product which is perceived as superior to patients educated on the disease.” In order to manipulate prescribers (doctors), Pfizer uses direct and indirect channels:

Prescribing existing and current patients with experimental drugs.

Obtain new patients with current drugs by telling patients about their illnesses.

Promote novel indications of providers with current drugs.

The organization mostly offers its drugs to pharmacy wholesalers, dealers, pharmacies, community departments and health maintenance organizations (HMOs). Vaccines are often marketed directly to clinicians.

Pfizer also receives capital from the Multinational Creative Pharmaceutical (GIP) industry through:

• Sales by pharmacies and hospitals of patent safe drugs to patients
• Out-licensing partner sales.

Pfizer makes money from the company of Global Vaccinations, Oncology, and Customer Healthcare (GVOC) via:

• Sales of oncology vaccines and products to patients through pharmacies and hospitals
• Out-licensing partner sales
• Direct purchasing of OTC goods by customers

Pfizer raises revenue from the Global Established Pharmaceutical (GEP) by:

• Sales of off-patented or near-lose patent items
• Generic medication purchases
• Injectable and bio-like sales to clinics and hospitals
• Revenues from co-promotion

The most successful cancer drugs of Pfizer

• Ibrance: In order to treat breast cancer, the most common form of cancer, Ibrance, a targeted biologic therapy used for chemotherapy, has been developed. The herbal substance has been licensed for usage in advanced and secondary breast cancer cases and is used in conjunction with hormone therapy. Ibrance functions by suppressing the effects of a female hormone (estrogen), which promotes tumor development. This helps slow down the disease’s development.
• “Sutent has been a standard of care for the treatment of advanced RCC since it was approved more than a decade ago, and is now the first approved adjuvant treatment option for certain patients at high risk of recurrent RCC—the most common type of kidney cancer,” Pfizer said in a statement.
• VIZIMPRO (dacomitinib) is a first-line therapy kinase inhibitor for patients with metastatic non-small cell lung cancer (NSCLC)
• LORBRENA (lorlatinib) is a drug used for the care of patients with non-small cell lung cancer (NSCLC).
• XTANDI can delay the progression of advanced prostate cancer.
• Bavencio (avelumab) has been approved as a first-line therapy for adult patients with advanced renal cell carcinoma (RCC), the most prevalent form of kidney cancer, in conjunction with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib). Bavencio is also approved for Merkel cell carcinoma, a rare skin cancer, and for second-line bladder cancer.
• In blood cancer therapy, Daurismo (glasdegib) tablets are used.
• Talazoparib tosylate is a U.S.-approved oral poly [ADP-ribose] polymerase (PARPi) inhibitor (PARPi) for the prevention of germline BRCA-mutated locally advanced or metastatic breast cancer.
• For those with progressive kidney cancer, Pfizer’s Inlyta medication is used.

What the Pfizer Vaccine Means for Investors

Pfizer and BioNTech announced a late-stage vaccine candidate that is at least 90% effective. The news sent shares of Pfizer up more than 7% on Monday alone. Pfizer’s news is encouraging, but investors shouldn’t go snapping up stocks just yet. Plenty of hurdles still remain, including detailed data, and there are still a lot of unknowns.

The first doses of the vaccine could be administered by the end of 2020, Pfizer says. “We expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021,” the company says.

Since the vaccine requires two shots, this breaks down to supply for 25 million people in 2020, it breaks down into 650 million in 2021. The economic value created would be orders of magnitude larger than any profits Pfizer andBioNTech reap for themselves. It’s fine for hedge funds to make a flurry of bets instantly based on this recent news. The U.S. government has an initial order of 100 million doses of the vaccine and an option to buy 500 million more.

Vaccines aren’t a blockbuster business for the health care industry. The vaccine race isn’t over, and the mRNA-based approach used by Pfizer and BioNTech is good news for the $34 billion Moderna (MRNA) Pfizer reported full-year profits of $16.3 billion in 2019, but the vaccine race is no game-changer for the giant health care company.

The Trump administration inked a $1.95 billion deal in July for 100m doses of any approved PFE/BNTX vaccine, which comes out to $19.50 per shot, an analyst says.  “It would be political suicide for a company to do so,” Haydock says, adding that price gouging on a must-have vaccine is a bad look no matter how you spin it. The mRNA-based approach used by Pfizer and BioNTech is good news for the $34 billion Moderna (MRNA) Pfizer reported full-year profits of $16.3 billion in 2019.

The vaccine race isn’t over, and there’s still a chance for other potential vaccines to make bottom-line impacts for shareholders. For the mega-cap companies pursuing a vaccine, the consumer and political goodwill from any successful vaccine is worth something in itself. The price gouging on a must-have vaccine is a bad look no matter how you spin it, analyst Haydock says.

The recent news from Pfizer and BioNTech is unequivocally positive. Investors looking to benefit from upcoming coronavirus vaccines should be patient and wait for more information. Smaller health care stocks like Moderna and Novavax arguably have the most upside potential from their own vaccine efforts, but investors have bid shares higher in 2020.

Top 5 biggest Pfizer competitors or Alternatives Stocks

1. Merck & Co.

Merck & Co., Inc. is a multinational corporation in the area of healthcare. Via its generic drugs, vaccinations, biologic treatments and animal welfare goods, the Organization provides health solutions. It works in four segments: pharmaceutical, animal welfare, healthcare and partnership facilities.

The Pharmacy Division of the Business contains pharmaceutical and vaccination drugs for human health that are sold either directly by the Company or by joint ventures.

2. Novartis International AG

Novartis AG is a holding company engaged in growth, manufacturing and selling of pharmaceutical products. The following segments operate: Innovative Drugs, Sandoz, and Corporate.

Researching, designing, manufacturing, supplying and marketing proprietary pharmaceuticals, the Advanced Drugs Division is comprised of two company units: Novartis Oncology and Novartis Pharmaceuticals. Formed on February 29, 1996, the organization has its headquarters in Basel, Switzerland.

3. Eli Lilly & Co.

Eli Lilly and Company is researching, designing, manufacturing and distributing human and animal medicinal drugs. Products from the organization are distributed in countries around the world.

Neuroscience, endocrine, anti-infective, cardiovascular agents, oncology, and animal health drugs are contained in the Eli Lilly products.

4. Bristol Myers Squibb

Bristol-Myers Squibb Corporation is a biopharmaceutical company worldwide. The Organization creates, permits, designs, markets and offers food and medicinal goods.

Bristol-Myers Squibb works on cancer, respiratory disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, liver donation rejection, and psychiatric disease drugs and new treatments.

5. Johnson & Johnson

For the consumer, pharmacy, and medical instruments and diagnostics industries, Johnson & Johnson produces health care goods and offers associated services.

In countries around the world, the organization offers items such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic instruments, and surgical devices.

List Major Companies Tied to the Pfizer Inc. Supply Chain

• Pharmaceutical Supply Chain Initiative (PSCI)
• The Institute for Sustainable Communities (ISC).
• Dow Inc.
• Thermo Fisher Scientific Inc.
• Illinois Tool Works Inc.
• Corning Inc.
• Avery Dennison Corporation

Top 10 Owners of Pfizer Inc.

• The Vanguard Group, Inc.
• SSgA Funds Management, Inc.
• BlackRock Fund Advisors
• Capital Research & Management Co.
• Wellington Management Co. LLP
• Geode Capital Management LLC
• Northern Trust Investments, Inc.
• Norges Bank Investment Management
• State Farm Investment Management Corp.
• BlackRock Investment Management Ltd.

3 Reasons to Buy Pfizer Stock

The report of imminent COVID-19 vaccinations appears to update the hopes of investors every day. But more than just the headline-grabbing coronavirus vaccine, BNT162b2, there are more reasons to purchase Pfizer stock.

• Vaccines:

The 95 percent efficacy in the prevention of SARS-CoV-2 infection has been demonstrated by Pfizer COVID-19 vaccine, produced with collaborator BioNTech. The first patients in the UK got the vaccination and obtained clearance for sale in Canada. The best-selling Pfizer product is now a vaccine. In 2019, Prevnar 13, pneumonia vaccination, meningitis and ear and sinus infections produced $5.85 billion in revenue.

• Ibrance:

The second best-selling medicine of the organization in 2019 was the Ibrance breast cancer drug. Drug revenues hit nearly $5 billion in 2019, reflecting development of 20% over 2018 and growth of 59% over 2017. Pfizer sued two drugs producers in India in attempt to prevent their attempts to introduce Ibrance generic variants until the patent expires in 2023.

• Emerging demands:

The scale and regional scope of Pfizer would render it a pioneer in the developed world. The latest spinoff and acquisition of Upjohn and Mylan by Pfizer is part of his plan to concentrate on these markets. In the U.S., gross revenue dropped by 8.4 percent from 2017 to 2019. In developing markets, however, revenue grew 11.7% during the same period.

Where Will Pfizer Be in 10 Years?

The $160 billion takeover by Pfizer of Allergan, Ireland, is expected to complete in the second half of 2016. Pfizer CEO Ian Read claimed that the tie-up will deliver more drugs and raise sales, not only cutting employment and other expenses.

Despite the flurry of deals during the last decade, Pfizer struggled to meet with its coworkers or the S&P 500. In the last ten years, the firm produced just an average total return of 5.2% on customers, compared with 7% for large drug companies and 6.43% for the S-P 500.

The wellbeing contributors of the Motley Fool offer their opinions about what could be ahead for Pfizer. Pfizer’s securities already practise almost 10 years and have proved to be able to deal with big sales surprises owing to the lack of patent rights. The patent cliff is a guessing game, but the new patent danger for Pfizer is maybe much less troubling than five years ago, and investors may want the firm to profit from the doubt.

The bulk of bestsellers in Pfizer will see their patents lapse by 2025, but neither of these products account for more than Lipitor’s gross quarterly sales in 2010. The biosimilar global market is projected at approximately $20 billion by 2020. Pfizer seems to be willing to win a pleasant portion of the sector.

While Pfizer has invested all the resources on oncology, it lags well behind the competition for the region’s cancer engines. The organization wants to applaud its immuno-oncology candidates, but they are both at step I or even earlier levels. Pfizer reports it predicts a modest rise to its sales in 2018, a 10% boost from Allergan’s acquisition in 2019 and a high-teen percentage increase in 2020. The sales of cancer products by the drug maker constitute just 4 percent of its $50 billion annual profits.

Over-confidence in M&A almost often destroys the R&D capability of an organization. The buying of Wyeth by Pfizer is a prime illustration. R&D was split half between the two firms, from approximately $12 billion to $6.5 billion following the merger.

And in an intense science area such as pharmaceuticals, where innovative medications are what drives the future, it is dangerous.

List of Drugs Pfizer currently have in development

Pfizer’s pipeline’s large majority of the operations concentrate on oncology and central nervous system disorders. Over recent years, the organization has measured and developed its R&D processes to bring essential innovative drugs and vaccines to patients in a sustainable flow.

As a result, 21 phase 3 clinical studies were ongoing worldwide on 27 October 2020.

Chief Executive Albert Bourla and lots of other peers have identified the vaccine and treatment pipeline, which Pfizer plans to raise annual sales by $15 billion by 2025. Increased purchases of current goods are projected to add an extra $8 billion in annual income, raising revenue this year from $41.6billion to $64.6billion in 2025.

Pipeline illustrates R&D advancement

• October 27, 2020 services
• 11 mature or modern programs
• Seven programs have stopped after last update
• 58 NMEs, 33 new indications and 1 biosimilar are included.

Products	Usage
BAVENCIO	For the maintenance of patients with locally progressive or metastatic urothelial carcinoma.
BRAFTOVI	For the care of adult patients who underwent previous systemic therapy for BRAFV600E-mutant metastatic colorectal cancer.
DAURISMO	In adult patients that are not eligible for conventional chemotherapy, for the care of recently diagnosed acute myeloid leukemia (AML).
NYVEPRIA	In patients taking myelosuppressive anticancer medicines with a clinically relevant prevalence of febrile neutropenia, the incidence of infection is reported to decrease.

Pfizer Inc. Capabilities

Pfizer Inc. is dedicated to discovering, developing, manufacturing, and selling healthcare products internationally. It operates through two main segments. These are:

1. Pfizer Innovative Health (IH)
2. Pfizer Essential Health (EH)

The IH segment develops and commercializes Pfizer products of medicines and vaccines, and consumer healthcare products in various therapeutic areas such as:

1. Internal medicine
2. Vaccines
3. Oncology
4. Inflammation and immunology
5. Rare diseases
6. Consumer healthcare, such as dietary supplements, pain management, gastrointestinal
7. Respiratory and personal care

These segment brands of the IH are as follows:

1. Prevnar 13
2. Xeljanz
3. Eliquis
4. Lyrica
5. Enbrel
6. Viagra
7. Ibrance
8. Xtandi
9. Advil
10. Centrum

The EH segment offers the following products dedicated in delivering essential health:

1. Branded generic products
2. Sterile injectable products
3. Biosimilars
4. Infusion systems

Brands of the EH segment are as follows:

1. Lipitor
2. Premarin family
3. Norvasc
4. Lyrica
5. Celebrex
6. Pristiq

Corporate and business services/agreements of Pfizer are as follows:

1. Contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc
2. Collaborative agreements with Eli Lilly & Company and Merck KGaA
3. Research collaboration and license agreement with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads to be used in drug development
4. Agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues for predicting drug induced liver injury

---

Pfizer Statistics

Pfizer revenue (annual)

• 2019: $51.75B, a 3.54% decline from 2018
• 2018: $53.647B, a 2.1% increase from 2017
• 2017: $52.5 billion
• 2016: $52.546B, a 0.53% decline from 2016
• 2015: $48.9 billion

Pfizer net income (annual)

• 2019: $16.273B, a 45.91% increase from 2018
• 2018: $11.885 billion
• 2017: $21.308 billion
• 2016: $7.215 billion
• 2015: $6.960 billion

Pfizer Frequently Asked Questions

When did Pfizer go public?

In June 1942, with an offer of 240,000 shares of common stock, Pfizer reincorporated in Delaware and went public.

How do I get a job at Pfizer?

You would need to conclude the recruiting procedure with the company in order to obtain jobs at Pfizer. Pfizer’s recruiting method includes several processes, including work applications and interviews where you are required to respond successfully to some questions to be recruited. Please visit careers.pfizer.com

Does Pfizer pay dividends?

Yes, Pfizer pays a $1.52 per share regular payout, for a 4.13 percent dividend yield. The next quarterly dividend payout from PFE will be rendered to approved shareholders on Friday, March 5. For the last 1 straight years, the organization has increased its dividend and is growing the dividend per year by an average of 6.27 percent.

51.53 percent of the sales are paid out as a payout from Pfizer.

Who is the auditor of Pfizer?

KPMG LLP audits Pfizer.

Where Pfizer products are manufactured?

In Belgium, China, Germany, Germany, India, Ireland, Italy, Japan, Singapore and the US, Pfizer has big production facilities. It runs about 50 plants around the world in total.

How many drugs does Pfizer make?

Pfizer Inc. produces, stores and distributes in the United States more than 312 medicines.

Is Pfizer the largest pharmaceutical company?

In 2020, the first leading pharmacy firm Pfizer claimed second position.

How many plants does Pfizer have?

Pfizer Global Manufacturing currently runs 78 plants worldwide with about 33,000 workers.

How did Pfizer Inc. start?

Pfizer was created by Charles Pfizer and Charles Erhart with the capital loan of Pfizer’s father.

Who created Pfizer Inc.?

Two recent German immigrants to the USA formed Pfizer in 1849, Charles Pfizer and Charles Erhart.

When and Where Pfizer Inc. started?

In 1849 Pfizer was established by two young German immigrants, Charles Pfizer and Charles Erhart, both men started up in a red brick building, Brooklyn factory, New York what was initially a fine chemical company.

The Takeaways:

At Pfizer, research and global tools have been implemented in any step of life to enhance health and wellbeing. The organization aims to establish expectations for safety, protection and value in the exploration, creation and manufacture of pharmaceutical products for citizens.

Its diverse worldwide range of health services covers biologic and tiny molecular drugs and vaccinations as well as several of the world’s best-known customers.

Pfizer colleagues from across the world collaborate every day to encourage health, safety, recovery and remedies that challenge the world’s most feared diseases. It also partners with health professionals, policymakers and local populations to promote and broaden the access to safe, accessible healthcare around the world in line with its responsibility as the world’s largest biopharmaceutical business.

Pfizer has been trying to create a positive for more than 160 years.